Pharmaceutical Company Sends Staff to Participate in Simulation Filling Technology Exchange
Release time:
2020-07-22
Pharmaceutical Company sent personnel to participate in the exchange of simulated filling technology
News 4# July 26 , Merck's medium simulated filling and 2020 Pharmacopoeia Law Update Exchange Meeting were held in Hangzhou. As the production base of sterile bulk drugs and sterile preparations of Jianfeng Pharmaceutical Company, Jinxi Factory of Jianfeng Pharmaceutical Company sent personnel to participate in the sharing meeting, learn about medium simulation filling and microbial content of Chinese Pharmacopoeia 2020 .
In this training, relevant staff of Merck Company, special experts of China Pharmaceutical Quality Association and Zhejiang Institute of Drug Inspection respectively shared and introduced the contents of medium simulation filling technology, problems involved in the process, and update of microbial detection content of Chinese Pharmacopoeia 2020 . At the same time, Merck also demonstrated equipment and projects such as microbial detection medium, microbial membrane filtration testing equipment, sterile testing and environmental monitoring systems in the training center.
Through technical exchanges, the trainees learned in advance about the microbial content to be updated in the new pharmacopoeia, and also had a deeper understanding of the operation of equipment such as buoyant bacteria samplers and culture media needed for daily production. (Lin Jianping)
Training Feeling
4 January 26 , another colleague and I had the honor to participate in Merck Medium Simulation Filling and 2020 Pharmacopoeia Regulation Update Exchange.
The keynote speakers of this meeting include Dunxin, a distinguished expert from China Medical Quality Management Association, Zheng Xiaoling, deputy director pharmacist of Zhejiang Food and Drug Inspection Institute, and Li Feng, Asia Pacific Regulatory Manager of Moker Life Sciences. Teacher Dunxin gave a lecture on the related topics of aseptic process simulation filling test, starting from three aspects: the necessity of simulation filling, the problems that often occur in audit inspection and the treatment of positive results. He mentioned that in the audit and inspection process he experienced in his career, he encountered many principled issues such as the authenticity of simulated filling, the antibacterial properties of simulated media, and whether the whole process of simulated filling is representative. As QA , I have participated in the aseptic process simulation filling test in the powder injection workshop for many times. In combination with what Mr. Dunxin said, I recalled the simulation filling test I participated in and found that our aseptic process simulation filling scheme is relatively complete, the design of interference factors is relatively comprehensive, and the implementation is ideal.
Li Feng and Zheng Xiaoling respectively introduced the general situation of Chinese Pharmacopoeia, the update of microbial detection content of 2020 edition, and the project progress of microbial rapid detection methods to the participants. They answered in detail the problems of microbiological testing encountered by the trainees in their work, and discussed the common problems of microbiological testing. Although microbiological examination is not my job, as a student majoring in bioengineering, I am still very interested in the current development of biotechnology. The content of this course makes me feel very useful.
In this short period of one day, I learned about the current development of the pharmaceutical industry in microbial testing, and also learned the relevant theoretical knowledge of aseptic process simulation filling technology. I discussed the problems encountered in my work with experienced experts and met several colleagues with outstanding abilities. This trip is really worth it! (lisa liao)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page